Pinnacle Dx: Pioneer in Smart Diagnostics Building Unattended Laboratories, Files IPO Prospectus

Ding Wei, founder of Pinnacles, has over 20 years of experience in the global in vitro diagnostics (IVD) industry, with extensive expertise in product R&D, strategic M&A, and sales management. He previously served as Global Vice President and President of Asia-Pacific at bioMérieux, and as President of Kehua Bio-Engineering, China’s first listed IVD company.

Ding Wei’s deep-rooted experience in the in vitro diagnostics (IVD) market has sharpened his sensitivity to industry trends. “China’s IVD industry has undergone a transition from open reagent systems to closed ‘instrument + reagent’ systems, and more recently, to the rise of laboratory automation lines. Automation lines, particularly those fully manufactured in China, represent a significant step for the industry, but not the ultimate endpoint,”Smart Laboratory Testing Will Be the Next Major Trend in In Vitro Diagnostics, Following Total Laboratory Automation”

Pinnacles focuses on the smart laboratory segment of in vitro diagnostics. Driven by clinical needs, it integrates traditional diagnostics with cross-disciplinary technologies to provide comprehensive smart laboratory solutions. The company is currently deploying smart laboratory robots, automated assembly lines, and products for clinical chemistry, immunoassay, and molecular diagnostics, with the goal of creating unattended laboratories. This initiative aims to help clinical laboratories improve the accuracy of test results, reduce costs, shorten report turnaround times, and optimize management.

The company has already garnered favor from top-tier investment firms such as Lilly Asia Ventures, ZhenFund, Oriental Fortune Capital, Qingsong Capital, and Vertex Ventures, securing nearly RMB 400 million in financing within less than two years of its establishment.

The National Health Commission has called for summarizing practical experiences in hospital informatization and establishing a “trinity” smart hospital system integrating medical care, services, and management. By applying technologies such as artificial intelligence, big data, cloud computing, and the Internet of Things to clinical scenarios, this initiative aims to comprehensively enhance the efficiency and quality of healthcare services. As an integral component of smart hospitals, smart laboratory medicine has rapidly developed under policy support. In recent years, demand for intelligent solutions among clinical laboratory departments has also surged.

Ding Wei, founder of Pinnacles, believes thatSmart Laboratory Medicine Has Three Key Features: Ultimate Automation, Integrated Information Management, and Clinical Decision Support.

Existing laboratory automation lines address 60%–70% of the automation needs in clinical laboratories. However, there is still room for improvement in the automation level during the processes of sample collection upon entry into the laboratory, verification, sorting, distribution to different testing centers, and loading onto analyzers. In the post-analytical phase, current automated management solutions, represented by smart refrigerators, are costly and lack flexibility.

The so-called ultimate automation is to achieveFull-process automation of laboratory management, from sample to result.

Furthermore, the Laboratory Information Management System (LIMS) currently used by the clinical laboratory suffers from information fragmentation, necessitating integrated interventions across different devices and systems.Information management integration has not yet been achieved。

Finally, to assist in clinical decision-making. In the future, the clinical laboratory will not only provide clinicians with simple result reports but also needs toProvide interpretation-related information and multi-marker trend analysis to facilitate clinical decision-making.

Ding Wei stated, “Smart laboratory testing has emerged in response to current needs; the key challenge is identifying a viable business model. Past experience indicates that deploying intelligent software solutions in isolation faces significant commercialization barriers within clinical laboratories.”Pinnacles’ strategy involves a comprehensive layout across devices, reagents, and software.”

Pinnacles’ core team comprises professionals from leading domestic and international enterprises, forming a comprehensive team that covers the upstream, midstream, and downstream segments, including instruments, reagents, and software. The company is developing and gradually launching a diverse portfolio of products—such as laboratory robotics, software, automated laboratory tracks, and high-speed biochemistry and immunoassay analyzers—to provide complete solutions for smart laboratory diagnostics. To date, Pinnacles has developed multiple robotic products, including specimen transport robots, which have been installed in dozens of Grade A tertiary hospitals across China. Its automated laboratory tracks and related supporting products are also poised for market launch.

Ding Wei positions Pinnacles as a pioneer in smart laboratory diagnostics, “We adoptBuild-Buy-Collaborate Model, with independent R&D as the core and strategic M&A and external collaborations as supplements, to rapidly refine its business layout, aiming to buildUnmanned Laboratory。”

The in vitro diagnostics (IVD) industry is currently experiencing a period of vibrant growth. According to Frost & Sullivan, the market size in China is projected to reach RMB 195.7 billion in 2024, with a compound annual growth rate (CAGR) of approximately 17.8% from 2019 to 2024, maintaining its rapid growth trajectory.

Currently, the in vitro diagnostics (IVD) industry is exhibiting several major trends. First, emerging technologies are continuously arising across various sub-sectors, including fourth-generation sequencing, microfluidics, molecular point-of-care testing (POCT), and mass spectrometry. Second, in terms of application scenarios, IVD is expanding from hospital laboratories to out-of-hospital settings such as homes and customs checkpoints. Third, the target population for testing has extended to include healthy individuals, with early cancer screening becoming a highly competitive sector. Fourth, leading enterprises are increasingly expanding overseas to establish a global presence.

Overall, the in vitro diagnostics industry is full of vitality, andSmart Laboratory Testing Will Be a Key Force Propelling Clinical Laboratories to New Heights.Ding Wei stated, “The gap between domestic clinical laboratories and their foreign counterparts in terms of specimen volume, level of automation, and hardware and software configurations will narrow, achieving cutting-edge and international standards.”

Of course, smart laboratory testing remains an emerging field globally. Although international giants have recognized the opportunities in this sector, they have yet to roll out comprehensive solutions, presenting a window of opportunity for Chinese enterprises.

“Over the past five years, China has made significant breakthroughs in industrial robotics and AI technology, and domestic top-tier tertiary hospitals have demonstrated a high level of awareness and acceptance of smart laboratory diagnostics. Benefiting from this,”China's smart laboratory medicine is set to undergo rapid development, achieving overtaking on the bend."Domestic enterprises will be a major force in providing smart laboratory solutions," said Ding Wei.

In the future, driven by the wave of smart laboratory medicine, Pinnacles will leverage smart laboratory solutions as its core competitiveness and aspire to build an enterprise-level platform for in vitro diagnostics.